Participants
Contact
Inbiomotion SL, a company focused on the development of a specific biomarker for the prediction of bone metastasis, has strengthened its board of directors with the appointment of Dr. David L. Lacey.
Inbiomotion SL is a spin-out company founded by Dr. Roger Gomis from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. The company is focused on the development of a specific biomarker for the prediction of bone metastasis from primary tumor biopsies. In July 2012 Inbiomotion closed a € 2 million Series A financing led by Ysios Capital. Inbiomotion’s proprietary single biomarker codes for a nuclear protein and is able to predict which patients will relapse to the bone. It has been initially validated with over 900 patient samples in two independent cohorts with three independent techniques (gene expression, IHC and ISH).
Read the full Press Release:
Inbiomotion, IRB Barcelona spin off, appoints Dr. David L. Lacey to its Board of Directors (PDF)
About IRB Barcelona
The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to cure cancer and other diseases linked to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society, and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 researchers and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).
